Godavari Biorefineries Limited posted a steady first quarter performance for FY 2025-26, with Revenue from Operations rising 2 per cent year-on-year to Rs 533.2 crore, supported by robust growth in the Bio-Based Chemicals segment, which registered a 43 per cent YoY jump in EBITDA.

Ethanol production for the quarter stood at 26,057 KL, aided by B-heavy molasses from the ongoing sugar season and the restoration of the Ethanol Blending Program from juice/syrup feedstock. The company also announced progress on its upcoming grain-based ethanol capacity, expected to provide a fresh growth lever in the coming quarters.

On the innovation front, Godavari advanced its drug discovery portfolio, securing European and Chinese patents for a novel anti-cancer molecule. The European patent has been validated in Spain, the UK, and as a Unitary Patent across multiple EU member states. Safety trials concluded with no dose-limiting toxicity (DLT), underscoring the molecule’s potential.

Despite operational resilience, the company reported a narrowed consolidated net loss of Rs 16.01 crore versus Rs 26.10 crore in Q1 FY25, citing seasonality in certain segments. Shares fell 5 per cent to Rs 279.30 on the BSE, hitting the lower circuit limit and extending the stock’s decline to 31.5 per cent from its 52-week high of Rs 408.25. Technically, the stock trades below its short-term moving averages (5-, 10-, 20-, 30-, 50-day) but remains above the 100- and 150-day SMAs.

“Q1 FY26 has been a quarter of resilience and progress for our company,” said Samir Somaiya, Chairman & Managing Director, Godavari Biorefineries. “We delivered growth in our Bio-Based Chemicals EBITDA, restored ethanol output momentum, and advanced our drug discovery pipeline with significant IP wins. Our upcoming grain-based ethanol capacity will further strengthen our growth trajectory.”

Godavari’s Q1 results position it as a multi-pronged bioeconomy player—balancing commodity-linked ethanol revenues with high-margin bio-chemicals and long-cycle pharmaceutical innovation.